Oncology

Oncology Review CME / CPD 

Full Course:  20 AMA PRA Category 1 Credits for CME / CEU / CPD

Short Course:  10 AMA PRA Category 1 Credits for CME / CEU / CPD

Course(s) are appropriate for:   Family Practitioners, Pediatricians, Internists, General Practitioners, Nurses, Nurse Practitioners, Physician Assistants (PA-C's)

Series 37 (ONC37) Topics Include:  Influence of Follow-Up Imaging, Side Effects of Treatment, Genetic Mutations, Treatment Combinations, Findings of the SWOG 8736 Trial, and more.

To view topic outline of the full or short course, select the Course Type (Full or Short) below:

Full Course:
ONC37
Full Course Price:
$580
Short Course:
ONC37A, ONC37B
Short Course Price:
$485
Format:
Available in Audio format.

Course Topics

Highlights from Advances in the Multidisciplinary Management of Lung Cancer

Estimate postoperative lung function in a patient undergoing pulmonary resection for high-risk lung cancer; Perform appropriate biomarker testing in patients with non-small-cell lung cancer; Describe the mechanism of acquired resistance in patients treated with tyrosine kinase inhibitors for non-small-cell lung cancer who have mutations in the gene for epidermal growth factor receptor; Recommend appropriate first-, second-, and third-line therapies for patients with squamous non-small-cell lung cancer.
5. List important side effects of antibodies and inhibitors used to treat non-small-cell lung cancer.

Highlights from the 22nd Annual Scottsdale Prostate Cancer Symposium 2017, Part 2

Explain the major findings of the ProtecT study; Manage active surveillance for low-risk prostate cancer; Characterize the risks and benefits of transrectal ultrasound-guided biopsy of the prostate; List risk factors for infection in men undergoing biopsy of the prostate; Counsel a patient asking about dietary interventions for prostate cancer.

Cancer of the Brain

Identify the various types of brain tumors and their epidemiology; Categorize brain tumors according to the updated World Health Organization classification; Implement evidence-based evaluation and new treatments for patients with brain tumor; Explain the rationale for combining radiation therapy and checkpoint inhibitors to treat brain cancer; Evaluate the evidence supporting combination therapy in the treatment of metastases to the brain.

Update on Melanoma and Sarcoma Therapy

Counsel a patient asking about the side effects of immunotherapies for metastatic melanoma; Select appropriate treatments for a patient with metastatic melanoma based on characteristics of the patient and the tumor; Explain how talimogene laherparepvec (T-Vec) is created; Critique a recent study that described a relationship between previous treatment with BRAF inhibitors and the effectiveness of immunotherapies for metastatic melanoma; Assess data of the efficacy of ipilimumab plus nivolumab, compared with nivolumab alone, in the treatment of sarcoma.

QUALIFIES FOR CLINICAL PHARMACOLOGY

Highlights from the 7th International Symposium on Malignant Pleural Mesothelioma

Assess data from recent trials that evaluated surgery or chemotherapy for mesothelioma; Counsel a patient with mesothelioma about the risks and benefits of antiangiogenic agents; Summarize current knowledge about biomarkers in patients with mesothelioma; Explain mechanisms of epigenetic regulation of gene expression in mesothelioma; Use tetrahydrouridine to improve outcomes of patients being treated with decitabine for mesothelioma.

QUALIFIES FOR CLINICAL PHARMACOLOGY

Screening for and Treatment of Cancer in Women

Explain the significance of mutations in BRCA genes in patients with ovarian cancer; Recognize the roles of the disease, the test, and the population when screening for cancer; List the advantages of liquid-based cytology over a conventional Papanicolaou test; Select appropriate candidates for screening mammography; Evaluate and counsel a patient who is concerned about her risk for ovarian cancer.

Assessment of Breast Cancer Risk

Distinguish between flat epithelial atypia and atypical ductal hyperplasia; Manage patients with premalignant lesions on core needle biopsy of the breast; List risk factors for upgrade to ductal carcinoma in situ or invasive breast cancer in a patient with atypical ductal hyperplasia; Counsel a patient asking about her genetic risk for breast cancer; Explain the roles of breast density and single nucleotide polymorphisms in risk for breast cancer.

Chronic Myeloid Leukemia/Multiple Myeloma

Explain the outcome of the EURO-SKI trial in patients with chronic myeloid leukemia; Compare ABL-001 with established therapies for chronic myeloid leukemia; List the side effects of contemporary treatments for multiple myeloma; Outline the shortcomings and benefits of dialysis for patients with myeloma cast nephropathy; Counsel a patient considering chimeric antigen receptor T-cell therapy for multiple myeloma.

QUALIFIES FOR CLINICAL PHARMACOLOGY

Highlights of the 22nd Annual Scottsdale Prostate Cancer Symposium 2017, Part 1

Critically evaluate emerging genomic tests that assess risk in patients with prostate cancer; Outline the findings of a survey of physicians that assessed the use of the cell cycle progression score to evaluate patients with prostate cancer; Explain the purported interaction between statins and androgen deprivation therapy; Interpret the findings of the SWOG S9346 study; Define androgen annihilation.

Update on Bladder Cancer

Weigh the benefits and risks of trimodal therapy and radical cystectomy in patients with muscle-invasive bladder cancer. 2. Implement strategies to improve local control of disease in patients with muscle-invasive bladder cancer; Recognize the variant subtypes of bladder cancer and their clinical implications; Choose an effective modality for managing nonmuscleinvasive bladder cancer of variant histology; Select patients with bladder cancer who are most likely to benefit from therapy using targeted agents.

Highlights from Advances in the Multidisciplinary Management of Lung Cancer

Estimate postoperative lung function in a patient undergoing pulmonary resection for high-risk lung cancer; Perform appropriate biomarker testing in patients with non-small-cell lung cancer; Describe the mechanism of acquired resistance in patients treated with tyrosine kinase inhibitors for non-small-cell lung cancer who have mutations in the gene for epidermal growth factor receptor; Recommend appropriate first-, second-, and third-line therapies for patients with squamous non-small-cell lung cancer.
5. List important side effects of antibodies and inhibitors used to treat non-small-cell lung cancer.

Cancer of the Brain

Identify the various types of brain tumors and their epidemiology; Categorize brain tumors according to the updated World Health Organization classification; Implement evidence-based evaluation and new treatments for patients with brain tumor; Explain the rationale for combining radiation therapy and checkpoint inhibitors to treat brain cancer; Evaluate the evidence supporting combination therapy in the treatment of metastases to the brain.

Screening for and Treatment of Cancer in Women

Explain the significance of mutations in BRCA genes in patients with ovarian cancer; Recognize the roles of the disease, the test, and the population when screening for cancer; List the advantages of liquid-based cytology over a conventional Papanicolaou test; Select appropriate candidates for screening mammography; Evaluate and counsel a patient who is concerned about her risk for ovarian cancer.

Chronic Myeloid Leukemia/Multiple Myeloma

Explain the outcome of the EURO-SKI trial in patients with chronic myeloid leukemia; Compare ABL-001 with established therapies for chronic myeloid leukemia; List the side effects of contemporary treatments for multiple myeloma; Outline the shortcomings and benefits of dialysis for patients with myeloma cast nephropathy; Counsel a patient considering chimeric antigen receptor T-cell therapy for multiple myeloma.

QUALIFIES FOR CLINICAL PHARMACOLOGY

Highlights of the 22nd Annual Scottsdale Prostate Cancer Symposium 2017, Part 1

Critically evaluate emerging genomic tests that assess risk in patients with prostate cancer; Outline the findings of a survey of physicians that assessed the use of the cell cycle progression score to evaluate patients with prostate cancer; Explain the purported interaction between statins and androgen deprivation therapy; Interpret the findings of the SWOG S9346 study; Define androgen annihilation.

Highlights from the 22nd Annual Scottsdale Prostate Cancer Symposium 2017, Part 2

Explain the major findings of the ProtecT study; Manage active surveillance for low-risk prostate cancer; Characterize the risks and benefits of transrectal ultrasound-guided biopsy of the prostate; List risk factors for infection in men undergoing biopsy of the prostate; Counsel a patient asking about dietary interventions for prostate cancer.

Update on Melanoma and Sarcoma Therapy

Counsel a patient asking about the side effects of immunotherapies for metastatic melanoma; Select appropriate treatments for a patient with metastatic melanoma based on characteristics of the patient and the tumor; Explain how talimogene laherparepvec (T-Vec) is created; Critique a recent study that described a relationship between previous treatment with BRAF inhibitors and the effectiveness of immunotherapies for metastatic melanoma; Assess data of the efficacy of ipilimumab plus nivolumab, compared with nivolumab alone, in the treatment of sarcoma.

QUALIFIES FOR CLINICAL PHARMACOLOGY

Highlights from the 7th International Symposium on Malignant Pleural Mesothelioma

Assess data from recent trials that evaluated surgery or chemotherapy for mesothelioma; Counsel a patient with mesothelioma about the risks and benefits of antiangiogenic agents; Summarize current knowledge about biomarkers in patients with mesothelioma; Explain mechanisms of epigenetic regulation of gene expression in mesothelioma; Use tetrahydrouridine to improve outcomes of patients being treated with decitabine for mesothelioma.

QUALIFIES FOR CLINICAL PHARMACOLOGY

Assessment of Breast Cancer Risk

Distinguish between flat epithelial atypia and atypical ductal hyperplasia; Manage patients with premalignant lesions on core needle biopsy of the breast; List risk factors for upgrade to ductal carcinoma in situ or invasive breast cancer in a patient with atypical ductal hyperplasia; Counsel a patient asking about her genetic risk for breast cancer; Explain the roles of breast density and single nucleotide polymorphisms in risk for breast cancer.

Update on Bladder Cancer

Weigh the benefits and risks of trimodal therapy and radical cystectomy in patients with muscle-invasive bladder cancer. 2. Implement strategies to improve local control of disease in patients with muscle-invasive bladder cancer; Recognize the variant subtypes of bladder cancer and their clinical implications; Choose an effective modality for managing nonmuscleinvasive bladder cancer of variant histology; Select patients with bladder cancer who are most likely to benefit from therapy using targeted agents.

Additional Information

Additional Continuing Medical Education options available:

Other courses of interest may include:  SurgeryFamily PracticeInternal MedicineObesity and Nutrition.

If you have taken the current Oncology CME / CPD Review listed above or if you are seeking additional credits, please visit: Medical Courses Coming Soon There you will find abbreviated listings of additional courses available related to this specialty and courses that are soon to be released.

For over 30 years, ASI has provided Continuing Medical Education, CME & CEU and Continuing Professional Development Education (CPD) for physicians and allied professionals in Oncology plus over 40 other specialties and subspecialties.  Lectures are recorded annually at the top seminars and conferences to provide the most current medical education to our clients.